ClinicalTrials.gg
RecruitingNCT06350032Updated Oct 29, 2026

Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH

A Phase 3 interventional study of preservative-free parenteral treprostinil in Pulmonary Arterial Hypertension, sponsored by AOP Orphan Pharmaceuticals AG. Recruiting at 5 sites in 5 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by AOP Orphan Pharmaceuticals AG · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.
Updated Oct 29, 20264 sites added4 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Pulmonary Arterial Hypertension with a site in Austria — 4 open to participants now, 6 under way, 4 of them phase 3. Pulmonary Arterial Hypertension · Austria.

Planned enrollment
46th of 48
20 · median 205
Started
2024
with 1 other
Phase 3
30 of 54
2 open now
Registered
53rd of 54
by date
Lead sponsor
3 of 54
AOP Orphan Pharmaceuticals AG

Among the 54 studies in Pulmonary Arterial Hypertension with a site in Austria, this one is the 46th largest by planned enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2024, is one of 30 in phase 3, and was the 53rd registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

4 of the 54 studies in Pulmonary Arterial Hypertension with a site in Austria are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Pulmonary Arterial Hypertension with a site in Austria, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate safety and tolerability of preservative-free parenteral treprostinil in paediatric patients with PAH (PH Group 1) who are below 18 years of age. The main question it aims to answer is:

  • if preservative-free parenteral treprostinil is safe and tolerable in the treatment of paediatric PAH in patients who are either prostacyclin-naïve or have been previously treated with commercially available parenteral treprostinil formulations.

Participants will receive either subcutaneous (SC) or intravenous (IV) preservative-free treprostinil and will be observed for 5 months (20 weeks ± 1 week).

Read the detailed description

In this study, a preservative-free treprostinil solution provided in a single-use vial will be used. Efficacy of treprostinil for the treatment of PAH in pulmonary hypertension (PH) Group 1 in children is reported throughout literature. However, since the removal of the preservative might impact the safe use of the parenteral solution for infusion, the safety profile of the newly developed preservative-free treprostinil solution will be assessed within this trial.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed by the parents or the legal representatives and written assent from appropriately aged participants
  2. Males or females from birth to under 18 years of age at the time informed consent was signed
  3. Confirmed diagnosis of severe PAH classified as PH Group 1 requiring a treatment with prostacyclin infusion
  4. Current diagnosis of PAH confirmed by right heart catheterisation (RHC) at screening or by historical RHC prior to screening with following haemodynamic findings:

    • Mean pulmonary arterial pressure (mPAP) >20 mmHg
    • Pulmonary vascular resistance Index (PVRI) >3 Wood Units (WU) m² If RHC is not possible due to medical reasons (e.g. neonates and infants), the confirmation by ECHO at the screening is sufficient.
  5. Prostacyclin naïve or patients pre-treated with SC or IV treprostinil prior to screening
  6. A subject is eligible to participate in this study, as assessed by the investigator, if they are of:

    • Non- (i.e., physiologically incapable of becoming pregnant); or,
    • Child-bearing potential - has a negative pregnancy test and is not lactating and, if sexually active, agrees to continue to use 2 reliable methods of until study completion and for at least 30 days following the last dose of study drug. Examples of reliable birth control methods include true abstinence as a lifestyle choice (periodic sexual abstinence method is not acceptable); the use of oral contraceptives; a reliable barrier method of birth control (diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices)

Exclusion criteria

Exclusion Criteria:

  1. Known intolerance to prostacyclin analogues
  2. PH related to conditions other than specified above
  3. Unrepaired congenital heart disease if surgery is planned within next 5 months
  4. Subjects diagnosed with any lung disease
  5. Acutely decompensated heart failure within previous 30 days from screening
  6. Subjects who have had an atrial septostomy or potts shunt within the previous 6 months of screening
  7. Any laboratory abnormality that precludes initiation or continuation of treprostinil therapy
  8. Moderate to severe hepatic dysfunction as defined by elevated liver function tests ( or alanine aminotransferase) ≥3 times the at Screening, or class B or C hepatic disease
  9. Subjects who are pregnant or breastfeeding
  10. Haematological abnormalities (e.g., severe anaemia, \<10 g/dL, leukopenia, White Blood Cells (WBC) \<2500/μL)
  11. History of substance use disorder, unless a proof of abstinence ≥1 year is provided
  12. Other concurrent severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
  13. Participation in another clinical trial of an investigational drug or device (including with placebo) within 30 days or 5 half-lives prior to screening, which-ever is longer
  14. Patients not able to handle pumps and infusion site if there is no parent, family member, guardian present in their household taking over pump handling or if they are not treated in hospital set-up
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    preservative-free parenteral treprostinil

    Patients will be treated with either SC or IV preservative-free treprostinil formulation. Dosing is not stipulated by the study protocol and will be done according to investigators discretion based on patient needs.

    Drug: preservative-free parenteral treprostinil

Interventions

  • Drugpreservative-free parenteral treprostinil

    Continuous infusion of either SC or IV preservative-free treprostinil. The dosing is not stipulated by the study protocol and will be done according to patient needs.

06

What researchers measure

Primary outcomes

  1. Frequency and seriousness of adverse events and adverse drug reactions

    The frequency and seriousness of adverse events and adverse drug reactions during the first 5 months (20 weeks ± 1 weeks) of treatment according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0).

    Time frame: 5 months (20 weeks ± 1 weeks)

Other outcomes

  1. Change from baseline in quality of Life (QoL)

    Change from baseline in quality of Life (QoL) as assessed by the Pediatric Quality of Life Inventory (PedsQoL Version 4.0) questionnaire. Rating from 0 (never) to 4 (almost always) per question. Questionnaire will be completed by pediatric patient (version appropriate for age group) and parents/caregivers.

    Time frame: 5 months (20 weeks ± 1 weeks)

  2. Change from baseline in 6-minute walk distance (6MWD)

    Change from baseline in 6MWD (patients \> 6 years)

    Time frame: 5 months (20 weeks ± 1 weeks)

  3. Change from baseline in World Health Organization Functional Class (WHO FC)

    Change in WHO FC class assessment based on current PH guidelines ranging from class I to class IV, whereas class IV means severe limitations.

    Time frame: 5 months (20 weeks ± 1 weeks)

  4. Change from baseline in echocardiography (ECHO) parameters - RA/RV enlargement

    right atrium (RA) / right ventricle (RV)

    Time frame: 5 months (20 weeks ± 1 weeks)

  5. Change from baseline in echocardiography (ECHO) parameters - RV systolic dysfunction

    Time frame: 5 months (20 weeks ± 1 weeks)

  6. Change from baseline in echocardiography (ECHO) parameters - RV/LV end-systolic ratio (PSAX)

    RV / left ventricle (LV)

    Time frame: 5 months (20 weeks ± 1 weeks)

  7. Change from baseline in echocardiography (ECHO) parameters - tricuspid annular plane systolic excursion (TAPSE)

    Time frame: 5 months (20 weeks ± 1 weeks)

  8. Change from baseline in echocardiography (ECHO) parameters - S/D ratio (TR jet)

    Time frame: 5 months (20 weeks ± 1 weeks)

  9. Change from baseline in echocardiography (ECHO) parameters - Pulmonary Artery Acceleration Time (PAAT)

    Time frame: 5 months (20 weeks ± 1 weeks)

  10. Change from baseline in echocardiography (ECHO) parameters - pericardial effusion

    Time frame: 5 months (20 weeks ± 1 weeks)

  11. Change from baseline in echocardiography (ECHO) parameters - eccentricity index

    Time frame: 5 months (20 weeks ± 1 weeks)

  12. Change from baseline in echocardiography (ECHO) parameters - acceleration time

    Time frame: 5 months (20 weeks ± 1 weeks)

  13. Change from baseline in plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels

    Time frame: 5 months (20 weeks ± 1 weeks)

  14. Treprostinil plasma concentration

    For treprostinil plasma concentration analysis one 0,5 ml blood sample for patients ≤ 20 kg and one 1ml blood (K3-EDTA) sample for patients \> 20kg will be taken.

    Time frame: 5 months (20 weeks ± 1 weeks)

07

Study locations

5 of 5 sites recruiting
  • Medizinische Universität Wien
    Vienna, State of Vienna 1090, Austria
    Recruiting
    • Sulaimi Albinni, MD · Principal investigator
  • Necker-Enfants Malades Hospital, Paris
    Paris, Paris 75015, France
    Recruiting
    • Damien Bonnet, Prof · Principal investigator
  • Gottsegen National Cardiovascular Center
    Budapest, Budapest H-1096, Hungary
    Recruiting
    • Laszlo Ablonczy, MD · Principal investigator
  • Pediatric Cardiac Center
    Bratislava, Slovakia
    Recruiting
  • Ramón y Cajal University Hospital
    Madrid, Madrid 28034, Spain
    Recruiting
    • Maria J del Cerro, Prof · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Nov 2028, 52 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's planned 52 months is close to that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2024
First posted
Apr 5, 2024
StartActual
Jul 31, 2024
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (1 Austria, 1 France, 1 Hungary, 1 Spain)
  • Medizinische Universität Wien · Vienna, Austria
  • Necker-Enfants Malades Hospital, Paris · Paris, France
  • Gottsegen National Cardiovascular Center · Budapest, Hungary
  • Ramón y Cajal University Hospital · Madrid, Spain
Show 4 removed
  • Medizinische Universität Wien · Vienna, Austria
  • Necker-Enfants Malades Hospital, Paris · Paris, France
  • Gottsegen National Cardiovascular Center · Budapest, Hungary
  • Ramón y Cajal University Hospital · Madrid, Spain
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    4 sites added, 4 sites removed
    Show 4 added (1 Austria, 1 France, 1 Hungary, 1 Spain)
    • Medizinische Universität Wien · Vienna, Austria
    • Necker-Enfants Malades Hospital, Paris · Paris, France
    • Gottsegen National Cardiovascular Center · Budapest, Hungary
    • Ramón y Cajal University Hospital · Madrid, Spain
    Show 4 removed
    • Medizinische Universität Wien · Vienna, Austria
    • Necker-Enfants Malades Hospital, Paris · Paris, France
    • Gottsegen National Cardiovascular Center · Budapest, Hungary
    • Ramón y Cajal University Hospital · Madrid, Spain
    + 4 other changes: index terms, identifiers, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06350032
Lead sponsor
AOP Orphan Pharmaceuticals AG
Responsible party
Sponsor
First posted
Apr 5, 2024
Start date
Jul 31, 2024
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

Clinical Project Manager
Contact
trepaed@aop-health.com
4366488375206

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion